Inclisiran (Leqvio<sup>®</sup>; Novartis) is a first-in-class, cholesterol-lowering small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine carbohydrates (GalNAc). Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterol...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!